West Conshohocken, Pennsylvania 19428

  • HIV Infections


To provide trimetrexate glucuronate to immunosuppressed patients with Pneumocystis carinii pneumonia (PCP) for whom this investigational compound could provide significant medical benefit.

Study summary:

Patients receive intravenous infusions of trimetrexate glucuronate and leucovorin for 21 days. Leucovorin is continued for 3 additional days after discontinuation of trimetrexate glucuronate.


Inclusion Criteria Concurrent Medication: Allowed: - Antiretroviral therapy (at the discretion of the treating physician and/or medical monitor). Patients must have: - Presumptive or definitive diagnosis of Pneumocystis carinii pneumonia (PCP). - HIV positivity or be otherwise immunosuppressed. - Demonstrated intolerance and/or resistance to trimethoprim/sulfamethoxazole during the course of therapy for the current episode and not candidates for parenteral pentamidine, OR a documented history of such intolerance during a prior episode. - Consent of parent or guardian if less than 18 years of age. NOTE: - In general, patients who meet the eligibility criteria for other U.S. Bioscience-sponsored clinical trials for trimetrexate would not be eligible for this Compassionate Use protocol. Exclusion Criteria Patients with the following prior conditions are excluded: History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis), exfoliative dermatitis, or other life-threatening reactions to trimetrexate.



Primary Contact:


Backup Contact:


Location Contact:

West Conshohocken, Pennsylvania 19428
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.